Elicit ads

Parantu Shah has spent 20+ years at the intersection of data, AI, and biopharma. On October 7 he'll share his hard-earned lessons from scaling AI systems at EMD Serono, Inc.(Merck KGaA, Darmstadt, Germany) in a fireside chat with with Elicit CEO, Andreas Stuhlmüller. We'll discuss: - What AI for drug development feels like from the inside - What "data readiness" means in practice, and how governance scales with it - How to earn trust in AI systems inside a regulated environment - How teams are measuring ROI on AI investments October 7, 9AM PT. Free to attend, register here: https://lnkd.in/gFmzUu-e

AI has become a useful research partner. It can find information, summarize evidence, and suggest ideas. But can it help us think better? Can it help us navigate the complex nuances of high-stakes decisions? Today, we’re taking the next step toward our mission of scaling up good reasoning for high-stakes decisions with the launch of the Elicit Research Agent, an AI environment built for high-stakes decisions. We built the Research Agent around these capabilities: 1. A harness with reasoning principles Reason with greater confidence with built-in models trained on BioDecisionBench, a benchmark designed to evaluate reasoning quality and handle uncertainty around decisions in pharma. 2. Diverse data sources Make decisions based on the full picture by synthesizing evidence across scientific literature, clinical trials, patents, regulatory and commercial sources, the web, and your own internal data. 3. Decision-ready outputs Move from research to decisions in a single workflow by turning evidence into fully cited reports, tables, analyses, visualizations, slides, and documents. 4. Transparency by default Trust and defend every decision with transparent methods trail and sentence-level citations. 5. Knowledge that compounds over time Improve each decision with Projects that keeps sources, context, instructions, and outputs connected in a single knowledge base. One of the most important new things we did was create BioDecisionBench, a benchmark specifically evaluating LLMs on reasoning failures in high-stakes pharma decisions. BioDecisionBench tests for reasoning around preclinical study design, observational study design (e.g. target trial validity), and rigorous reasoning throughout the drug development process. When we evaluate on BioDecisionBench, Elicit highlights more key considerations for decisions (76.7% coverage in Elicit Smartest mode vs. 68.8% for Claude Opus 5 Max). Read the full evaluation blog: https://lnkd.in/gGmPJXQ9. Early customers are already using Research Agent to prioritize indications, shape clinical strategy, design trials, develop laboratory methods, inform market entry, and strengthen patent strategy. Read the launch post and see examples of Research Agent in action: https://lnkd.in/gSTQq_Ks You can use the Research Agent today at elicit.com or access it through API (https://docs.elicit.com) to bring its capabilities into your own workflows.

Over the past year, Orion Pharma, a leader in human and veterinary medicines, has gone deep with Elicit. The team began using the platform in the early days of Reports and Systematic Literature Reviews, and more recently expanded that work with the launch of our Research Agent. Serhii Vakal, PhD, Lead ML/AI Scientist at Orion Pharma, shared a compelling story about how he used Elicit to search, collate, extract, and interpret large volumes of scientific literature far more efficiently than manual review. Work that previously required going paper by paper can now be completed in a fraction of the time, helping Orion Pharma evaluate more targets with the same team and reach each assessment earlier. We're excited to see how Orion Pharma continues to build on this work as Elicit supports its early discovery workflow. Read the full case study: https://lnkd.in/gxrTDmaw

Elicit Systematic Review now supports PRISMA 2020 guidelines. You can also run reviews programmatically via API. Major upgrades include: - Search, screen, extract up to 40,000 papers in real-time - Dual review - Full-text screening - Decision logs & exclusion reasons - Multiple search strategies using boolean, keyword, MeSH, or semantic search, across multiple databases - 100% reproducibility for keyword search - PRISMA diagrams for every exclusion decision - Custom report templates - The API We're also releasing new screening and extraction models evaluated across 108 published Cochrane reviews that achieve: - 95% recall of papers included in published Cochrane reviews - 97% sensitivity and 93% specificity on abstract screening - 99.5% sensitivity and 70% specificity on full-text screening - 96% accuracy in data extraction Upgrades to Elicit Systematic Review and the Systematic Review API are immediately available to Enterprise customers. Existing Scale users and those who sign up in the next 30 days will receive 1 trial review with these upgrades. Systematic reviews are the gold standards of evidence synthesis. Evidence synthesis is the bedrock of good decision-making. Elicit's mission is to radically increase good reasoning for high-stakes decisions. Details below.

Walk into every KOL meeting with the evidence already mapped. Use AI-powered literature review to surface pivotal studies faster.

Elicit launched as an AI Connector inside Benchling yesterday. What does this mean for scientists? When working in Benchling — exploring experimental results, reviewing ELN entries, digging into the registry — and you need to know what the published literature says, Elicit is right there. Search tens of millions of papers, find assay precedents, pull in relevant findings, without leaving your notebook. And this isn't just surfacing links. Every result comes with citations traced back to the source paper: claims you can actually verify, not just titles to click through. Your internal R&D data and the external evidence base, connected with the rigor to trust what comes back. This is where scientific work is heading: proprietary data and published evidence, reasoned over together, in one place. We've been building toward exactly this, meeting scientists where they already work, with the depth and transparency Elicit is known for. Congrats to the Benchling team on the launch. Excited to learn from early users and keep pushing what's possible for R&D teams. #Benchling #MCP #LifeSciences #RAndD #AI #EvidenceSynthesis